Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2025-01-01 DOI:10.2174/0113816128352935250116064725
Iman Bagherpour, M R Mozafari, Seyed Morteza Naghib
{"title":"Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.","authors":"Iman Bagherpour, M R Mozafari, Seyed Morteza Naghib","doi":"10.2174/0113816128352935250116064725","DOIUrl":null,"url":null,"abstract":"<p><p>Neurodegenerative disorders (NDs) are highly prevalent among the aging population. It primarily affects the central nervous system (CNS), but the effects are also observed in the peripheral nervous system. Neural degeneration is a progressive loss of structure and function of neurons, which may ultimately involve cell death. The blood-brain barrier (BBB), which separates peripheral blood circulation from the central nervous system, is essential for maintaining intracerebral homeostasis. Drug delivery systems based on nanomaterials (NDDSs) employ nanoparticles (NPs) as their drug transport vehicles. Moreover, nanotechnologybased methods usually involve numerous nanosized carrier platforms, which potentiate the effect of the therapeutic agents in the therapy of NDs, especially in diagnosis and drug delivery, with negligible side effects. In addition, nanotechnology-based techniques have offered several strategies to cross BBB to intensify the bioavailability of drug moieties in the brain. In the last few years, diverse kinds of nanoparticles (NPs) have been developed by incorporating various biocompatible components (e.g., polysaccharide-based NPs, polymeric NPs, selenium NPs, AuNPs, protein-based NPs, gadolinium NPs, etc.), that showed great therapeutic benefits against NDs. The discussion concluded with a look at the opportunities and problems that come with NDDSs in modern basic and clinical research.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":"1998-2024"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128352935250116064725","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Neurodegenerative disorders (NDs) are highly prevalent among the aging population. It primarily affects the central nervous system (CNS), but the effects are also observed in the peripheral nervous system. Neural degeneration is a progressive loss of structure and function of neurons, which may ultimately involve cell death. The blood-brain barrier (BBB), which separates peripheral blood circulation from the central nervous system, is essential for maintaining intracerebral homeostasis. Drug delivery systems based on nanomaterials (NDDSs) employ nanoparticles (NPs) as their drug transport vehicles. Moreover, nanotechnologybased methods usually involve numerous nanosized carrier platforms, which potentiate the effect of the therapeutic agents in the therapy of NDs, especially in diagnosis and drug delivery, with negligible side effects. In addition, nanotechnology-based techniques have offered several strategies to cross BBB to intensify the bioavailability of drug moieties in the brain. In the last few years, diverse kinds of nanoparticles (NPs) have been developed by incorporating various biocompatible components (e.g., polysaccharide-based NPs, polymeric NPs, selenium NPs, AuNPs, protein-based NPs, gadolinium NPs, etc.), that showed great therapeutic benefits against NDs. The discussion concluded with a look at the opportunities and problems that come with NDDSs in modern basic and clinical research.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于无机纳米颗粒的神经退行性疾病药物递送系统的治疗。
神经退行性疾病(NDs)在老年人群中非常普遍。它主要影响中枢神经系统(CNS),但也影响周围神经系统。神经变性是神经元结构和功能的逐渐丧失,最终可能导致细胞死亡。血脑屏障(BBB)将外周血循环与中枢神经系统分开,对维持脑内稳态至关重要。基于纳米材料(ndds)的药物输送系统采用纳米颗粒(NPs)作为其药物运输载体。此外,基于纳米技术的方法通常涉及许多纳米级载体平台,这增强了治疗药物在NDs治疗中的效果,特别是在诊断和药物递送方面,副作用可以忽略不计。此外,基于纳米技术的技术提供了几种穿越血脑屏障的策略,以增强药物部分在大脑中的生物利用度。在过去的几年里,通过加入各种生物相容性成分(如多糖基纳米粒子、聚合物纳米粒子、硒基纳米粒子、AuNPs、蛋白质基纳米粒子、钆纳米粒子等),各种纳米粒子(NPs)被开发出来,显示出对NDs的巨大治疗效果。最后讨论了NDDSs在现代基础和临床研究中带来的机遇和问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
期刊最新文献
Therapeutic Potential of Stem Cells in the Treatment and Management of Immunomodulatory Disorders. Reshaping the Future of MASLD - From Pathophysiological Mechanisms to New Therapeutic Horizons. Exosomes in Osteoarthritis: Emerging Roles in Pathogenesis, Diagnosis, and Therapeutic Potential. Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy. Unveiling Heart Failure: Gender-Specific Insights and Innovations in Women's Cardiac Health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1